DES and pancreatic neoplasm: However, if dual immunolabeling is not affordable, performing single desmin and CD31 labeling may be beneficial for patients with pancreatobiliary tract cancers because increased the number of foci of VI is known to be an important factor associated with worse survival in patients with surgically resected pancreatic cancers [12].